tetracyclins), 15 or the 50S ribosomal subunit and obstruct the exit tunnel (macrolide antibiotics, eg, erythromycin). 16 Peptidoglycan interfering antibiotics operate by either blocking the transport of peptidoglycan monomers across the cytoplasmic membrane or inhibiting transpeptidases and transglycosidases that are pivotal for the formation of peptide cross-links or formation of glycosidic bonds, respectively. 9 Antibiotics that disrupt bacterial membranes are cationic cyclic peptides with fatty acid chains (polymixins). They intercalate with the bacterial membrane to modulate its permeability and thereby cause membrane disruption. 17 However, the discovery of additional targets is essential to counteract the increasing drug resistance displayed by several validated targets against which drugs are available.
| DIHYDROFOLATE REDUCTASE
DHFR is an important enzyme in the de novo pathway of purine and thymidine synthesis. Small molecules targeting this enzyme have demonstrated utility as potential antibiotics. 2 There are two main variants of EcDHFR that are either chromosomally encoded or plasmid encoded. Plasmid-encoded type II R67 EcDHFR from trimethoprim (TMP)-resistant bacteria are especially interesting since they are genetically unrelated to chromosomal EcDHFR. R67 EcDHFR is a homotetramer and is structurally distinct, both at the overall protein-fold level and at the active site, from chromosomal
EcDHFR. The episomally encoded EcDHFR is also fascinating from the perspective of multiple levels of regulation demonstrating positive co-operativity in binding the substrate DHF and negative co-operativity in binding the cofactor NADPH 18 that could be potentially harnessed in an inhibitor-discovery project. While it would be desirable to discuss small molecules that target both chromosomal and plasmid-encoded DHFR from the perspective of antibiotic discovery, the current review exclusively focuses on chromosomal DHFR as a model system. This is because of the availability of a large amount of structural and mechanistic data for the latter and its indispensable nature for the survival of the microorganism, making it an ideal target for drug discovery. The enzyme converts DHF to tetrahydrofolate by hydride transfer from the cofactor NADPH to the C6 atom of the pterin ring and an additional concomitant protonation at N5. At cellular concentrations of the cofactor and substrate and under steady-state conditions, the catalytic cycle of EcDHFR goes through five kinetic intermediates: E:NADPH (holo enzyme), E:DHF:NADPH (Michaelis complex), and E:THF:NADP + , E:THF, and E:THF:NADPH (the product complexes). 19 DHFR is the sole source of cellular tetrahydrofolate and thus plays an important role in the maintenance of tetrahydrofolate pools. Tetrahydrofolate is an important precursor of purine and thymidine synthesis, and thus is critical for growth and proliferation of cells. Consequently, targeting DHFR is lethal for rapidly proliferating cells like cancer or bacterial cells. Several classes of compounds have been explored for their potential antifolate activity, among the most prominent are diaminoquinazoline, 20 diaminopyrimidine, 21, 22 diaminopteridine, 23 and diaminotriazines. 24 DHFR inhibitors that have found widespread application in therapy are methotrexate (MTX) (used in chemotherapy against cancer cells and rheumatoid arthritis), TMP (for bacterial DHFR), and pyrimethamine (PYR; against Plasmodium falciparum DHFR).
However, in spite of continuous efforts to discover novel small-molecule inhibitors of this enzyme, most studies exclusively rely on quantitative structure-activity relationship (QSAR)-based elaboration of known antifolates to discover novel small molecules. 25 Moreover, the rapid acquisition of drug resistance by the enzyme compounds the challenges associated with drug discovery. It was recently demonstrated that the laboratory-based selection of E. coli cells resistant to TMP showed step-wise acquisition of resistance phenotype mainly localized on either the promoter or the substrate binding site of the enzyme DHFR. 26 Mutations in the DHFR amino-acid coding region were P21L, A26T, A26V, A26S, L28R, W30C, W30G, W30R, and I94L, respectively, and have been either shown or predicted to affect DHFR enzymatic activity. 26 Three of these mutations (c-35t, P21L, and W30R) have also been reported from clinical isolates, 26 four (P21L, A26T, W30R, and I94L) have been reported in laboratory selection and four (L28R and W30C in the coding region and −35C>T and −9G>A in promoter) appeared in independent selection experiments performed on agar plates. Furthermore, there has been extensive documentation of mutations in DHFR leading to drug resistance in pathogenic organisms like P. falciparum, Streptococcus pneumoniae, etc. [27] [28] [29] Hence, it is necessary to keep discovering novel small-molecule inhibitors for this enzyme.
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| NEXT GENERATION FOLD-BASED AND POCKET-BASED VLS
In VLS, computer algorithms predict the likelihood of a particular small molecule interacting with the protein target of interest. 30 Subsequently, these predictions are assessed by a high-throughput experimental screening of the predicted ligands for binding to their protein target. Thus, VLS can reduce the number and kinds of molecules that have to be screened experimentally, thereby saving both time and cost. Recently, the introduction of various statistical, filtering, and informatics protocols has fostered the efficient integration of experimental and in silico screening methodologies resulting in enhancing their importance in drug discovery. 31 There are two distinct types of VLS protocols to identify potential lead molecules: structure-based and ligandbased virtual screening (VS). Traditional structure-based approaches rely on the presence of a high-resolution structure for the target protein. 32 Then, molecular docking of the ligand to the protein target is often employed as it does not require a priori knowledge of known binders. 33 Furthermore, they can also target a specific binding pocket of interest. In practice, molecular docking employs empirical force fields to compute the free energy of interaction of the small molecule with its protein target. However, to a large extent, the accuracy of its predictions depend upon the quality of the receptor's structure, accessory information about its dynamics 34 and the availability of a uniform high-quality validation set. 35 It has been demonstrated that docking accuracy may be reduced by almost 90% if the structure employed has a root-mean-square deviation of greater than~1.5 Å from the native state. 36, 37 Thus, it is very sensitive to rather minor structural distortions. Furthermore, the reliability of the docked poses depends upon aspects like water molecule locations, the small-molecule conformational ensemble, and the accuracy of the force field. 38 A variant of structure-based VLS is fragment-based drug discovery whereby weakly binding fragments to the protein target of interest are fused together in silico to arrive at a lead molecule for subsequent organic synthesis and assessment. [39] [40] [41] [42] However, implementing in silico approaches to fragment discovery has remained challenging because of the low binding affinity of the fragments and the inability of existing force fields to differentiate binders from nonbinders. 43 In some cases, the absence of high-resolution structures has been compensated for by the use of homology models that have been refined and manually cross-checked for accuracy. [44] [45] [46] Some examples of structure-based VS approaches include AutoDock, Dock, FlexX, Glide, Gold Surflex, ICM, LigandFit, and eHiTS. 33 As pointed out above, the major rate-limiting step associated with structure-based drug discovery is the presence of either a high-resolution protein structure or a confidently predicted protein model. However, not all protein targets are amenable to X-ray crystallography-based structure determination or high-resolution structure prediction (due to the lack of appropriate template structures). The problem becomes all the more acute for membrane anchored proteins or large macromolecular complexes. To circumvent this limitation, ligand-based VS approaches have been developed. 47 Though ligand-based VS approaches are robust, they require at least one known small-molecule compound that binds to the protein target of interest. These methods focus exclusively on the comparative molecular similarity analysis of the ligand demonstrated to bind to a particular protein target with molecules in a database. Some ligand-based VS approaches rely on Tanimoto coefficient two dimensional (2D) fingerprint, 48 pharmacophore, 49 or three dimensional (3D)-based shape similarities 50 between the known binder and database molecules. Ligand-based VS does not provide information about the site of binding in the protein and requires an experimentally determined bioactive compound. Thus, it is clear that both traditional structure-based and ligand-based VS, though advantageous, possess their fair share of limitations, especially vis-à-vis therapeutically relevant proteins, many of which are either membrane proteins lacking substantial structural information [51] [52] [53] or lacking known binding ligands.
To overcome the limitations of the above two classical approaches, hybrid methods that rely on structural and ligand similarity combined with evolution-based ligand-binding information have been pioneered by our group [54] [55] [56] ( Figure 2 ). These approaches encompass both global structural similarity and pocket similarity. To address these issues, PoLi, a new pocket centric approach capable of targeting specific binding pockets in holo-protein templates, was developed 60 ( Figure 2 ). This method takes advantage of our recent demonstration that the number of stereochemically distinct ligand-binding pockets is small and likely complete. 61, 62 PoLi can target specific ligand-binding pockets in the target protein, does not rely on the similarity between the template and the target at the global fold level and implements both 2D and 3D small-molecule similarity approaches to identify ligands from holo templates. 60 More specifically, the method models the target protein, predicts their ligand-binding pockets, aligns the predicted pockets to database of holo pockets, copies, and prunes the ligands from the holo pocket to weight the binding pharmacophore, and then undertakes ligand-based VS approaches with both 2D and 3D similarity metrics to come up with a ranked prediction for experimental assessment. This method was benchmarked extensively in silico followed by high-throughput experimental validation on EcDHFR. As expected, the experimentally obtained hits not only belonged to those that were already obtained by FINDSITE comb but also included ligands excised from evolutionarily and structurally unrelated protein scaffolds. 60 Finally, apart from these above mentioned approaches, we have also successfully developed a new iterative combined pocket detection with an interaction-weighted ligand-similarity search-based approach to obtain high affinity binders for the olfactomedin domain of human myocilin implicated in glaucoma. 63 
| CLASSIFICATION OF DHFR INHIBITORS
| Substrate and cofactor analogs
Conventional classes of DHFR inhibitors are heterocyclic with one to three nitrogen atoms in the ring and two amino groups arranged in the para position. They are mostly analogs of the substrate DHF 64 and all have been characterized for their potency of DHFR inhibition. 4 ,20,24,55,60 A few classes have been kinetically characterized in detail to understand their site and order of binding. 20, 24 Results from these studies indicate that all bind to the DHF binding site in the enzyme, and hence, competitively displace the substrate. Unlike the substrate DHF that can bind to the enzyme with or without the cofactor nicotinamide adenine dinucleotide phosphate (NADPH), the binding of these inhibitors is ordered in nature and conditional upon NADPH binding. As mentioned earlier, prominent classes of conventional DHFR inhibitors are diaminotriazines, diaminopteridines, diaminoquinazolines, and diaminopyrroloquinazolines. 20, 24, 55, 60 Analogs of the NADPH cofactor have also been explored as potential inhibitors of DHFR. 65 Pyridine nucleotides NADP, nicotinamide-hypoxanthine dinucleotide phosphate (NHDP), ε-NADP, acetylpyridine-adeninedinucleotide phosphate (APADP), and nicotinamide adenine dinucleotide (NAD) function as analogs of NADPH and inhibit the enzyme in a linear competitive fashion vis-à-vis NADPH and linear noncompetitive fashion vis-avis DHF. 65 However, the reduced and oxidized forms of thionicotinamide adenine dinucleotide phosphate inhibit the enzyme such that it shows linear noncompetitive inhibition with respect to both NADPH and DHF.
Furthermore, adenosine 5ʹ-phosphate, adenosine 2ʹ-phosphate, adenosine diphosphate (ADP)-ribose and NAD all preferably bind to the free enzyme to form the E.I binary complex compared with their affinity for the enzyme-DHFR complex. Analogs such as adenosine 2ʹ,5ʹ-diphosphate, adenosine triphosphate (ATP)-ribose, APADP, NHDP, ε-NADP, and NADP show increased affinity for the enzyme-DHF form to make the ternary complex over the free 66 This seems to be a novel route to inhibit DHFR and could be tested in bacteria provided that the bacterial homolog is as unstable as the mammalian one in the absence of the cofactor.
| Classical and nonclassical inhibitors
Yet another classification of DHFR inhibitors is based on their chemical structures. According to structural differences, inhibitors have been classified as either classical or nonclassical 67 ( Figure 3 ). Classical inhibitors are folate analogs that possess a heterocyclic ring (most often a pteridine) that is linked to an aryl group and a glutamate tail. For this group to inhibit DHFR, they need to be imported into the cell through folate transporters (RFC-1's in eukaryotes 68 ) and need to be polyglutamylated by folylpolyglutamyl synthetase On the contrary, nonclassical inhibitors do not possess the glutamate tail. This confers both desirable and undesirable properties on them to be used as drugs. The desirable properties include uptake by passive diffusion through the membrane, and thus, they do not require any transporters. However, the undesirable effects include reduced water solubility, and, not being the substrate for FPS, they are incapable of being polyglutamylated, resulting in possible reduced retention inside the cell subsequent to uptake. A few examples of this class of inhibitors include TMP, PYR, trimetrexate, and piritrexim ( Figure 3 ).
| Membrane permeability as a factor in DHFR inhibitor discovery
Antibiotic development faces two-fold challenges in terms of affinity of the small molecule for its intended target to bring about inhibition and bioavailability. The latter indicates the amount of the small molecule that can cross the cytoplasmic membrane and outer membrane (in the case of Gram-negative bacteria), either actively or passively, for it to be available to interact with its target. 74 With regard to uptake, aqueous porins on the outer membrane of Gram-negative bacteria facilitate the passive uptake of selected small molecules that are subsequently taken up by the cells (traversing the inner membrane) by either passive diffusion or active transport. This process of uptake should essentially be faster than possible efflux mechanisms operational at any given time. 74 The success or failure of an antibiotic-discovery initiative, to a large extent, depends on determining the membrane permeability of the small molecule apart from studies that throw light on its interaction with the target of interest. A judicious combination of the above two factors in determining the structure-activity relationship based medicinal chemistry synthesis of derivatives is ideal for successful antibiotic discovery.
EcDHFR is a cytosolic enzyme. As such, the high negative charge on classical DHFR inhibitors at physiological pH makes them unsuitable for passive diffusion through the membrane, thereby making bioavailability issues for this class of inhibitors a major issue. As briefly discussed in Section 5.2, this problem is compounded by a lack of conventional folic acid transporters due to the reliance of E. coli on de novo folate SRINIVASAN ET AL.
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synthesis. Thus, classical DHFR inhibitors like MTX, which is extensively used in chemotherapy in mammalian cells, have a poor MIC above 1 mM for E. coli despite their high affinity for the purified bacterial enzyme.
Mutations in acrA or tolC, resulting in inactivation of the TolC-dependent AcrAB multidrug resistance efflux pump, result in an~10-fold reduction in MIC (the MIC drops from 1 mM to about 0.064 mM) indicating that efflux plays a major part in the MTX resistance of E. coli. 75 Having said that, the MIC still does not correlate well with the low nanomolar affinity of MTX for the in vitro enzyme.
On the contrary, nonclassical inhibitors can diffuse passively through cell membranes. A prominent example includes TMP, which is weakly basic at physiological pH and shows potent cytotoxicity for E. coli (its MIC is Recently, it has also been demonstrated that zwitterionic compounds such as propargyl-linked antifolates are DHFR inhibitors of Gram-negative bacteria and can diffuse passively across the cell membrane. These hybrid antifolates, according to the authors, conserve the features made by negatively charged glutamate tails while being permeable across the bacterial cell membrane. 78 Our studies that employ fold-based hybrid VLS approaches (Section 6) were successful in picking analogs with both acidic tails and no tails. 20, 24, 55, 79 However, the best inhibitors had long tails with localized negative charges.
These group of inhibitors, we posit, would face the same kind of troubles discussed above in terms of cell permeability. For instance, the top nine best compounds tested from our studies (along with appropriate positive The 2,4-diaminopteridine and diaminopyrimidine templates are known as DHFR inhibitors. As pointed out above, the main representative of the family diaminopteridine is MTX, a potent inhibitor of DHFR. 82, 83 Our work spanning both fold-based FINDSITE comb54,55 and pocket-based PoLi 60 was successful in recapturing MTX. Previously, MTX has been shown to be a slow onset, tight-binding inhibitor of the E. coli enzyme. 20, 83 Inhibition by MTX obeys a mechanism where there is a rapid initial formation of an enzyme-NADPH-inhibitor complex followed by its slow isomerization to trap the inhibitor. 84 Further, it has also been shown that MTX binds to the folate binding site (competitive with respect to folate) and its binding on the enzyme is conditional upon NADPH binding. 85 TMP, the most successful inhibitor against bacterial DHFR as far as the antibacterial effect is concerned, belongs to the diaminopyrimidine class. Our studies with fold-based VLS were always successful in recapturing this group of compounds as positive controls. inhibitors of eukaryotic DHFRs. 24, 94 Cycloguanil, a derivative of linear aliphatic proguanil, is the most prominent example as it is a potent inhibitor of P. falciparum DHFR. 95, 96 Extensive QSAR analysis of the inhibition by the diaminotriazine series of compounds has been carried out on DHFR analogs from several different organisms. 24, 25, [97] [98] [99] [100] [101] [102] [103] Finally, hybrids of triazines also demonstrate inhibitory activity on DHFRs. 104 Most studies have focused on understanding the inhibitory effect of diaminotriazines or their hybrids on DHFRs from eukaryotic sources, mainly P. falciparum, since they show poor affinities for the prokaryotic enzyme. To address this issue, we used systematic QSAR analysis and insights obtained from docking studies to design appropriate inhibitors employing analogs of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine (PDTD), as potent inhibitors of EcDHFR ( Figure 6 ). Our study was the first attempt at detailed mechanistic characterization of the diaminotriazine family of compounds by inhibition kinetics to assess their effect on EcDHFR. 24 Fifteen analogs of PDTD showed binding to EcDHFR as assessed by differential scanning fluorimetry, and subsequently showed inhibition of the enzyme. NSC120927 was the best hit obtained from this study of 1,3,5-triazine-2,4-diamine class of molecules and is the first ever to show potent inhibition of a DHFR isoform from Gram-negative prokaryotes. We also explored the kinetic mechanism of inhibition by 1,2,4-triazine-3,5-diamines on EcDHFR. Detailed kinetic characterization demonstrated that, like diaminopyrroloquinazolines, this class of compounds also bind to the active site of the enzyme and their binding is conditional upon NADPH binding. However, the best hits obtained from this study failed to show slow onset of tight binding inhibition indicating that the k off rates are not as slow as for the best hit from the diaminopyrroloquinazoline group of compounds. This is indicative of the short residence time on the enzyme, and hence, would require further organic synthesis efforts to design better inhibitors. Having said that, this study has opened up the possibility of exploring a new class of molecules that could potentially yield novel antibiotic candidates against Gram-negative bacteria.
| ATYPICAL CLASSES OF INHIBITORS TARGETING THE EcDHFR ALLOSTERIC SITE AND THE POCKET-BASED VLS APPROACH: DEOXYBENZOIN, STILBENE, AND CHALCONES
PoLi, the pocket-based VLS algorithm, was used to perform VLS on EcDHFR. This yielded a set of small molecule predictions that were assessed by high-throughput experimental screening employing differential scanning fluorimetry. Most of the hits belonged to the conventional classes of DHFR inhibitors as elaborated in Section 6. 
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However, a few weak binders were novel, small-molecule scaffolds with no similarity to known classes of DHFR inhibitors (see next paragraph) and with no previous report of them interacting with DHFR from any organism whatsoever. 60 Using conventional QSAR and systematic scaffold hopping, we assessed a series of small-molecule chalcones, stilbenoids, and other chemically similar scaffolds for their EcDHFR binding/inhibition potential. 80, 81 Six stilbenoid compounds (resveratrol, oxyresveratrol, SITS, DIDS, flavonic acid, and DNDS), three chalcone derivatives and ononetin showed binding and inhibition of EcDHFR. This demonstrated that the general requirement for this class of molecules to inhibit EcDHFR involves small molecules possessing 3 to 4 degrees of freedom connecting the two benzene moieties, with appropriate hydrogen bonding acceptors or donors on the ring. 80, 81 However, no information was available on the site or order of binding for this novel class of inhibitors. To address these questions, we performed detailed competition assays with substrate and cofactor of the small molecules. The resultant kinetic patterns demonstrated that the compounds, under concentrations that might be physiologically relevant, showed uncompetitive or linear mixed-type inhibition with respect to substrate DHF indicating that they do not bind to the substrate binding site as is the case with other EcDHFR inhibitors 80 ( Figure 7) . Furthermore, in a behavior reminiscent of other inhibitors, their binding is conditional upon NADPH binding. This implies that the inhibitors bind to a unique site distinct from either the substrate or the cofactor binding site, and hence, reports on a cryptic 105 site on EcDHFR that is formed in the fully ligated ternary form of the enzyme. It has to be stated here that targeting cryptic sites is projected as one of the main challenges in designing small-molecule drugs against target proteins and our demonstration opens up the avenue for discovery of such cryptic sites in other drug targets. 106 However, we would like to point out that there have been a few previous investigations that have tried to understand allosteric binding in DHFRs. One study, investigating nanobody binding in EcDHFR, showed that there are two epitopes to which the nanobody binds. 107 They predict that epitope α is a new allosteric site that is over 10 Å away from the active site, and nanobody binding to that site results in conformational restraints and alterations of protein dynamics in EcDHFR, causing either activation or inhibition. 107 Another study has pointed to the role of M42, a residue distal to the active site in EcDHFR, as being an allosteric site that regulates protein dynamics and thus turnover at the active site. 108 Employing a sequence based approach, yet another study has tried to demonstrate the network of residues that are involved in facilitating the conformational transition from the closed state to occluded state and vice-versa. 109 The resveratrol binding site predicted by us (residues I2, P105, K106, A107, and Q108) 80, 81 is distinct from the sites in the above mentioned previous studies. While the allosteric pocket in the nanobody study comprises residues V10, D11, H114, I115, D116, E118, F140, S150, Y151, C152, 107 the dynamics study points to M42 as a crucial residue that impacts the dynamics of the enzyme. 108 The class of inhibitors that were discovered, apart from their ability to inhibit wild-type EcDHFR, are also capable of inhibiting drug-resistant rescue variants of the enzyme (a drug-resistant rescue variant of DHFR is defined as the form of DHFR that is enriched due to natural selection during persistent drug challenge and mostly possesses mutations at the inhibitor binding site, making it refractory to inhibitor binding). We assessed their behavior on three drug-resistant variants of EcDHFR (the L28R single mutant and the A26T/L28R and P21L/L28R double mutants). 80 They inhibited these variants with as much potency as for the wild-type enzyme ( Figure 7) .
Further, the inhibitors exhibited toxicity against E. coli strains that harbored the drug-resistant variants. It must be emphasized that none of the conventional classes of DHFR inhibitors were capable of inhibiting either the drugresistant variants of EcDHFR nor did they display cytotoxic effects against the microorganisms that harbored such drug-resistant variants. Thus, these new molecules represent interesting antibiotic hits that are worthy of future development. 80, 81 To appreciate the significance of the above finding vis-à-vis discovering novel inhibitors for the drug-resistant variant of EcDHFR, it is essential to understand the literature on the types of ligand-protein interactions and their advantages and disadvantages, respectively. The below section, in brief, summarizes the various types of ligandprotein interactions that are known.
| MONOTHERAPY/POLYTHERAPY AND MONOVALENCY/BIVALENCY/ MULTIVALENCY
There are various modes whereby ligands (small molecules or protein) interact with their target of interest to bring about the desired physiological outcome (Figure 8 ). The most common kind of interactions are monovalency and/or monotherapy whereby a single small molecule is designed to interact with one target of critical importance for the physiological outcome. 110 Polytherapy is the utilization of more than one small molecule to target different receptor molecules or target pathways to achieve the desired outcome. 111 Both monotherapy and polytherapy are F I G U R E 7 Design of allosteric site binders for E. coli dihydrofolate reductase capable of inhibiting both the wild-type and the drug-resistant variants of the enzyme SRINIVASAN ET AL.
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widely employed in clinical practices to counteract conditions such as epilepsy, psoriasis, depression, and cancer, but their advantages and disadvantages remain a topic of debate.
110
Multi/polyvalency is another emerging concept in the ligand-protein interaction field, whereby a multivalent ligand comprised of multiple copies of ligands conjugated to scaffolds, allows the simultaneous binding of multivalent ligands to multiple binding sites or receptors. 112 Polyvalency has properties that are distinct from monovalent interactions in terms of conferring higher specificity and affinity. A few representative differences include achieving higher affinity of interactions for ligands with less surface area, signal amplification by nonlinear graduation in biological response through possible induction of positive co-operativity, induction of oligomerization as a means of regulating the outcome, and inhibiting or suppressing undesirable interactions between ligands and nonspecific targets. 113, 114 Bivalency is a minor modification on the concept of multivalency whereby bivalent ligands, which are composed of two similar/distinct functional pharmacophores linked by a spacer, can interact with either similar/distinct pockets on target protein/proteins. 115, 116 A typical example of a bivalent ligand interacting with distinct pockets on a target protein is bitopic orthosteric/allosteric ligands of G protein-coupled receptors. 117 Another prominent example, especially vis-à-vis folate metabolism, is the discovery and synthesis of dual inhibitors that target both DHFR and thymidylate synthase in humans. 118 However, to the best of our knowledge, none of the studies to date has explored in considerable detail the application of two distinct untethered small molecules targeting two distinct pockets on the same protein's surface. The section below expands on the idea of targeting the allosteric pocket and the orthosteric pocket on the enzyme EcDHFR as a means of designing potent antibiotics which could have possible roles in killing drug-resistant E. coli.
| COMBINATORIAL THERAPY: TARGETING ALLOSTERIC AND ACTIVE SITES SIMULTANEOUSLY
Why do we need novel classes of molecules targeting unique allosteric pockets on the enzyme DHFR? Will this new strategy prevent the acquisition of drug resistance? Are we attempting to suggest that allosteric sites, somehow, are less prone to mutation induced resistance acquisition? The answer, of course, is no. Mutations at the active site on DHFRs that confer drug resistance impose fitness costs on the organism 119 that may, to some extent, impose stringent conditions upon the acquisition of such mutations. In other words, there is more selective pressure on the active site and hence more severe penalties in terms of fitness lost due to mutations on the active site. However, allosteric sites are organism specific [120] [121] [122] [123] and, to the best of our knowledge, are almost unknown in EcDHFR indicating that they may be either dispensable or are under less evolutionary pressure and hence, likely to be more mutable.
Having said that, it is well documented in the literature that small molecules targeting the substrate and cofactor binding pockets, the usual targets for the development of novel drugs in EcDHFR, have a tendency to evolve resistance by the acquisition of mutations. 26 This is because of the selection of variants that can confer an evolutionary survival advantage by having either reduced or no binding for the small-molecule drug. However, novel allosteric pockets, which have not been previously targeted for small-molecule inhibitor discovery are a sterile niche for inhibitor discovery. These pockets, at the least, represent repositories of cavities that could be exploited for overcoming the drug resistance acquired by the original substrate binding site. Moreover, combined administration of folate binding-site targeting small molecules and molecules that bind to the novel pocket may represent a stringent conditional probability that demands the presence of mutations in both the pockets for resistance acquisition against both small molecules. Even if
we assume that such mutations exist in both the pockets, the probability of such an event happening simultaneously will be rarer than a unique mutation in just one of the pockets. Moreover, simultaneous mutations in both pockets may constrain the loop dynamics of the enzyme in such a way that might not be beneficial for the fitness of the organisms harboring such double mutants. In addition, it might be difficult to acquire an array of compensatory mutations to restore the fitness that the organism lost 124 in selecting for mutations at both the active and allosteric sites to become refractory to an antibiotic. Not only is this a far lower probability event, but the acquisition of two mutations might result in significant destabilization of the native protein structure which will increase the population of unfolded molecules. By implication, its ability to generate the requisite levels of the enzyme product will therefore be reduced.
Furthermore, there is an opinion in the literature that allosteric inhibitors are more selective and less toxic than those that target orthosteric sites. [125] [126] [127] Additional arguments that support the design of inhibitors for allosteric sites rather than the active site include the lack of homolog level resolution which would likely happen if the active site were targeted.
Further, active-site binding molecules are all inhibitors rather than modulators of the enzyme activity.
Modulation is a more desirable property than inhibition since the latter has the disadvantage of shutting down the enzyme activity, basal levels of which might be pivotal for survival. Furthermore, active site binding small molecules will be competitive inhibitors of the enzyme. Assessment of the IC 50 for the competitive model of inhibition is trickier than that for noncompetitive inhibition. 128 This is because of the substrate concentration dependence of the former's potency. Under equilibrium conditions, an increase in substrate concentration can effectively displace the competitive inhibitor and shift the IC 50 rightward. Hence, competitive inhibition is reversible by an increase in substrate concentration that likely happens in the absence of substrate turnover in the proximity of the enzyme. 128 Assuming that the rate-limiting step in an enzyme-catalytic cycle is product release (and not the chemical step) (which is the case with chromosomally encoded EcDHFR), most of the enzyme species under steady state condition would be product bound. This might also hold true for the physiological form of the enzyme. Hence, designing small molecules that can target the product-bound holo enzyme form (with either noncompetitive or uncompetitive inhibitors) might yield a better outcome as compared with targeting the apo-form with competitive inhibitors. 129 Moreover, targeting allosteric sites, as in the case of uncompetitive or noncompetitive inhibition, makes more sense. In the case of uncompetitive inhibition, the inhibitor can trap the substrate bound complex that may be evident as an increase in the affinity of the inhibitor for the enzyme resulting in leftward IC 50 shift. 129 This leftward shift is because an increase in substrate concentration in the absence of substrate turnover will push the equilibrium towards the substrate or product-bound form of the enzyme that, in turn, is the SRINIVASAN ET AL.
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preferable receptor for the small-molecule inhibitor. In a recent paper from our group, we introduced the concept of COmposite protein LIGands (COLIG) whereby more than one ligand binds to a pocket on the protein's surface, which interact with each other as well as the protein within a single ligand-binding pocket. 130 We have also demonstrated, by a systematic analysis of the structures deposited in the protein data bank (PDB), how uncompetitive kinetics of EcDHFR paves the way for exploration of further cases of uncompetitive inhibition as potential targets of drug discovery. 130 These arguments, coupled with the wide resurgence of interest in targeting allosteric sites for drug discovery, 131, 132 support the justification for selection of allosteric pockets for drug discovery.
| CONCLUSIONS AND FUTURE PERSPECTIVES
Development of resistance due to mutations is a persistent problem in DHFR, in particular, and one of the mechanisms of antibiotic resistance, in general. Given the important role that this enzyme plays and that it is indispensable to the survival of the microorganisms that harbor it, it is important that continuous efforts be invested in discovering new and improved inhibitors for this enzyme. Our work with next generation VLS approaches has shown that we can predict a handful of candidates to be screened as compared with traditional approaches, 55 and yet, we have not only been successful in predicting novel small-molecule inhibitors belonging to the traditional inhibitor scaffold but also in predicting novel allosteric inhibitors for the enzyme. Though extensive follow-up work is required to translate the discoveries from the lab to conferring benefits in human health and wellbeing, our approaches show the potential power of the application of this novel VLS methodologies for discovering small-molecule binders and inhibitors for both very well studied, and hence saturated, and novel refractory targets implicated in many human diseases.
